To explore the role of integrin ␣5␤1 in proliferative vitreoretinopathy (PVR) pathogenesis by evaluating the expression ␣5␤1 on ARPE-19 cells and patient proliferative membranes, quantifying the inhibitory effects of JSM6427 (a small molecule ␣5␤1 inhibitor) on ARPE-19 cell adhesion and migration, and assessing the therapeutic potential of JSM6427 in a rabbit retinal detachment model. METHODS. Expression of ␣5␤1 was evaluated on activated ARPE-19 cells by flow cytometry and on PVR membranes by immunohistochemistry. ARPE-19 cells were used in fibronectin-dependent adhesion and migration assays with various concentrations of JSM6427; IC 50 was calculated. In the rabbit model, eyes were intravitreally injected with vehicle or JSM6427 on day 0 or 1 after retinal detachment; BrdU was administered intravitreally on day 3, and retinal tissues were harvested on day 3 (4 hours later) or 7. Retinal scarring, cellular proliferation, and inflammatory responses were quantified, and retinal morphology was analyzed in retinal sections. RESULTS. Activated ARPE-19 cells and PVR membranes expressed high levels of ␣5␤1; expression was low in control eyes. JSM6427 provided a dose-dependent blockade of ARPE-19 cell adhesion to fibronectin (IC 50 , 7.1 Ϯ 2.5 M) and inhibition of migration (IC 50 , 6.0 Ϯ 4.5 M). In the rabbit model, intravitreal injection of JSM6427 provided significant inhibition of proliferation of retinal cells (Müller cells, microglia, and macrophages) on days 3 and 7 after detachment and inhibition of inflammatory response and retinal scarring on day 7 after detachment. CONCLUSIONS. JSM6427 is a promising treatment for PVR, with data suggesting that inhibition of ␣5␤1-fibronectin interactions addresses multiple pathways involving retinal pigment epithelial, glial, and inflammatory cells. (Invest Ophthalmol Vis Sci.
PURPOSE.
To explore the role of integrin ␣5␤1 in proliferative vitreoretinopathy (PVR) pathogenesis by evaluating the expression ␣5␤1 on ARPE-19 cells and patient proliferative membranes, quantifying the inhibitory effects of JSM6427 (a small molecule ␣5␤1 inhibitor) on ARPE-19 cell adhesion and migration, and assessing the therapeutic potential of JSM6427 in a rabbit retinal detachment model. METHODS. Expression of ␣5␤1 was evaluated on activated ARPE-19 cells by flow cytometry and on PVR membranes by immunohistochemistry. ARPE-19 cells were used in fibronectin-dependent adhesion and migration assays with various concentrations of JSM6427; IC 50 was calculated. In the rabbit model, eyes were intravitreally injected with vehicle or JSM6427 on day 0 or 1 after retinal detachment; BrdU was administered intravitreally on day 3, and retinal tissues were harvested on day 3 (4 hours later) or 7. Retinal scarring, cellular proliferation, and inflammatory responses were quantified, and retinal morphology was analyzed in retinal sections. RESULTS. Activated ARPE-19 cells and PVR membranes expressed high levels of ␣5␤1; expression was low in control eyes. JSM6427 provided a dose-dependent blockade of ARPE-19 cell adhesion to fibronectin (IC 50 , 7.1 Ϯ 2.5 M) and inhibition of migration (IC 50 , 6 .0 Ϯ 4.5 M). In the rabbit model, intravitreal injection of JSM6427 provided significant inhibition of proliferation of retinal cells (Müller cells, microglia, and macrophages) on days 3 and 7 after detachment and inhibition of inflammatory response and retinal scarring on day 7 after detachment. CONCLUSIONS. JSM6427 is a promising treatment for PVR, with data suggesting that inhibition of ␣5␤1-fibronectin interactions addresses multiple pathways involving retinal pigment epithelial, glial, and inflammatory cells. (Invest Ophthalmol Vis Sci. 2010;51:1028 -1035) DOI:10.1167/iovs.09-3575 P roliferative vitreoretinopathy (PVR) is an aberrant woundhealing process characterized by intraocular inflammation, cellular proliferation, and scarring. 1 A common complication of primary rhegmatogenous retinal detachment with an estimated risk ranging from 5% to 12%, PVR also is associated with other conditions such as penetrating ocular trauma and retinal translocation surgery. 2 The management of PVR by vitrectomy has limited success in terms of visual benefits, 2 even when adjunctive treatments, such as daunorubicin 3 or 5-fluorouracil plus heparin, 4, 5 are administered. Current experimental pharmacologic treatments for retinal detachment and PVR based on nonspecific inhibition of cell proliferation have been unsuccessful so far, indicating that there is a great need for new therapeutic approaches.
The pathogenesis of PVR involves a wide variety of cell types, including retinal pigment epithelial (RPE) cells, monocyte/macrophages, microglia, glial cells (astrocytes, Müller cells, and perivascular glia), and fibroblasts/myofibroblasts. 1,6 -8 Evidence suggests that transdifferentiation of migrating RPE cells is a critical early step in PVR pathogenesis, 1, 9 with Müller cell activation 10 and hypertrophy onto the retinal surface also being centrally involved in the formation of contractile epiretinal membranes. 11 Migration and adhesion of dislocated RPE cells have been shown to be mediated primarily through interactions between fibronectin (FN) and the FNspecific integrin, ␣5␤1.
12 Both ␣5 and ␤1 integrin subunits 13 and the corresponding ligand FN 14 -16 have been detected in proliferative retinal membranes, including those associated with PVR. The concentrations of FN in eyes of patients with PVR tended to increase with the severity of clinical stage, suggesting that elevated levels of FN in the subretinal fluid and in the vitreous may represent an early event in the pathogenesis of PVR. 17 Cytokines and growth factors, such as interleukin-1␤, interleukin-6, tumor necrosis factor (TNF)-␣, transforming growth factor (TGF)-␤, platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF), also play an important role in promoting the pathogenesis of PVR. 12,18 -23 Notably, bFGF, EGF, and PDGF have been found to promote RPE cell proliferation, 20, 21 and TNF-␣ has been shown to induce adhesion, migration, and upregulation of ␣5␤1 integrin expression on RPE cells. 12 Furthermore, bFGF has been shown to stimulate Müller cell proliferation and epiretinal membrane formation in an animal model, 22 whereas PDGF, TGF-␤, and insulin-like growth factor have been shown to promote tractional force generation by Müller cells in vitro.
small (590-Da) molecule inhibitor of the ␣5␤1-FN interaction, 24 with good tissue penetration and stability in physiological buffers. JSM6427 has a selectivity at least 1,700-fold greater for ␣5␤1 than for other integrins (␣v␤3, 1,700-fold; ␣v␤5, 7,500-fold; ␣3␤1, 100,000-fold) expressed in normal RPE 25 and has been shown to result in a dose-dependent reduction in FN-mediated ERK-1/2 phosphorylation in ARPE-19 cells. 26 The present studies were designed to explore the role of integrin ␣5␤1 in PVR pathogenesis by evaluating the expression ␣5␤1 on ARPE-19 cells and on proliferative membranes from patients with PVR, by quantifying the inhibitory effects of JSM6427 on ARPE-19 cell adhesion and migration, and by assessing the effects of JSM6427 on retinal scarring, cellular proliferation, inflammation, and Müller cell hypertrophy in a rabbit model of retinal detachment.
MATERIALS AND METHODS

Flow Cytometric Analysis of Integrin Expression on ARPE-19 Cells
Antibodies were purchased from BD Pharmingen (Heidelberg, Germany) (␣5, BD555651, clone VC1; ␣v␤3, BD555504, clone 23C6; ␣4, BD555501, clone 9E10; secondary antibody, BD550874) or from Millipore (Schwalbach, Germany) (␤1, MAB1951F, clone P4G11; ␣v␤5, MAB1961Z, clone P1F6). The integrin ␤1 antibody was directly conjugated with fluorescein isothiocyanate. ARPE-19 cells (LGC Promochem-ATCC, Wesel, Germany) were incubated in phosphate-buffered saline (PBS)/1% heat-inactivated fetal calf serum (FCS)/50 nM phorbol myristate acetate (PMA), and primary anti-integrin antibodies (0.4 -1 g/mL) for 30 minutes; negative control cells were incubated without a primary antibody. The cells were incubated with allophycocyanin-conjugated secondary antibody (1 g/mL; BD550874), washed with PBS/1% FCS after each incubation step, and analyzed by flow cytometry (FACSCalibur; BD Bioscience, San Jose, CA).
ARPE-19 Adhesion Assay
ARPE-19 cells were grown to 80% confluence in Dulbecco's modified Eagle's medium (DMEM)/Ham's F12 medium (Biochrom AG, Berlin, Germany) supplemented with 10% FCS and 2 mM glutamine on 96-well plates coated with 10 g/mL FN (Millipore) and blocked with 1% bovine serum albumin (BSA). The cells were detached with cell dissociation solution (Sigma-Aldrich, Taufkirchen, Germany) and incubated in 25 mM HEPES/150 mM NaCl/2 mM EDTA (pH 7.4). They were transferred to EDTA-free buffer with 50 nM PMA and 2 mM MgCl 2 and incubated for 15 minutes. Serial dilutions of JSM6427 or antibodies IIA1 (integrin ␣5␤1; BD Pharmingen), MAB1976Z and MAB1961Z for ␣v␤3 and ␣v␤5 (Millipore), respectively were added. A stock solution of JSM6427 (Jerini AG, Berlin, Germany) was prepared in dimethyl sulfoxide (DMSO). DMSO concentrations were adjusted for all samples and did not exceed 0.5%. Cells (5 ϫ 10 4 cells/well) were plated on FNcoated plates for 45 minutes at 37°C and washed once with PBS. Adherent cells were fixed (5% glutaraldehyde), rinsed with PBS, and stained with 0.1% crystal violet. After the plates were rinsed with PBS, 10% acetic acid was added and the plates were analyzed at 570 nm (Spectra Max M5 microplate reader; Molecular Devices, Sunnyvale, CA). The experiments were performed in triplicate. The concentration required for 50% inhibition (IC 50 ) was determined by computer (XLfit software; IDBS, Guildford, UK). The data were analyzed by one-way analysis of variance and are presented as the mean Ϯ SD.
ARPE-19 Migration Assay
The undersides of cell migration filters (8 m pore; Transwell BD Falcon HTS FluoroBloc; VWR International, Darmstadt, Germany) were coated with 10 g/mL FN (120 kDa fragment; Millipore) and blocked with 2% BSA. ARPE-19 cells grown to 80% confluence in DMEM/Ham's F12 medium (Biochrom AG) and to quiescence in DMEM/Ham's F12 medium/0.1% BSA without FCS (assay medium) were trypsinized and washed. The cells (2.5 ϫ 10 4 ) were preincubated in assay medium containing 10 ng/mL bFGF with the same concentrations of JSM6427 as in wells, plated in the upper compartment, allowed to migrate through the filters for 5 hours, and then stained with 4 M calcein AM (Invitrogen, Carlsbad, CA) in Hanks' balanced salt solution. All experiments were performed in triplicate. Fluorescence was measured at 485/538 nm (SpectraMax M5 reader; Molecular Devices). The mean fluorescence for cells cultured in the absence of bFGF was valued at 100%. For some experiments, photographs were taken by a masked observer, and the total area of fluorescence was quantified with imageanalysis software (ImageJ software), and IC 50 was determined (XLfit software; IDBS). The value for cells incubated with bFGF was set at 100% and the background of noncoated, BSA-blocked wells was subtracted. For cytotoxicity assays, ARPE-19 cells were grown for 2 days in the presence of serial dilutions of JSM6427. The cells were subsequently fixed, stained with crystal violet, and quantified as described for adhesion assays.
Evaluation of Integrin Expression on Human PVR Membranes
Procedures were conducted in conformance with the principles of the Declaration of Helsinki, and the patients gave informed consent. Thirteen patients with disorders associated with pathologic preretinal membranes (PVR associated with retinal detachment, n ϭ 8; idiopathic epiretinal membranes, n ϭ 5) underwent surgical removal of the membranes. The membranes were fixed (4% paraformaldehyde), transferred to PBS, and paraffin embedded. Similarly processed retinal tissues from three pyogenic granulomas served as a positive control for ␣5␤1 labeling, whereas sections from a glaucomatous eye and an eye with a uveal melanoma (taken from an area distinct from the tumor) were used as normal controls. Sections were deparaffinized and rehydrated, microwaved in 0.01 M citrate buffer (pH 6.0), washed twice in purified water, blocked with 5% Tris-buffered saline (TBS)/1% BSA, and washed three times with TBS/1% BSA.
Immunohistochemistry was performed with mouse monoclonal anti-human (1:700, MAB1969, Millipore) or polyclonal rabbit anti-␣5␤1 (1:6000, AB1928 or AB1921; Millipore) primary antibodies diluted in TBS/1% BSA. All antibodies showed similar staining patterns. Vasculature was labeled with polyclonal rabbit anti-human von Willebrand factor antibody (1:50,000, A0082; Dako, Hamburg, Germany), macrophages were labeled with mouse monoclonal anti-human, CD68 (1:50, PG-M1, Dako), glial cells were labeled with mouse monoclonal antihuman glial fibrillary protein (1:400, GFAP; 6F2, Dako), and RPE cells were labeled with monoclonal mouse anti-human CK18 (1:500, Cy-90; Sigma-Aldrich). Primary antibodies were detected with an ABC assay (StreptABComplex/HRP Duet Mouse/Rabbit kit; A0492; Dako) and sections were counterstained with Mayer's Haemalaun.
Rabbit Model of Retinal Detachment
All experimental procedures conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and to the guidelines of the facility Animal Resource Center. Before the procedure, rabbits were sedated with an intramuscular injection of xylazine (3 mg/kg)/ketamine (15 mg/kg; Henry Schein, Inc., Melville, NY), and proparacaine was applied topically to the eye (Henry Schein, Inc.). Approximately one half of the inferior retina was detached in the right eyes of adult New Zealand Red pigmented rabbits by infusing hyaluronate sodium (Healon; Pharmacia, Piscataway, NJ) in 0.25% balanced salt solution via a glass pipette between the neural retina and RPE (sodium hyaluronate was used to prevent retinal reattachment). In three eyes with retinal detachments, 1 mg JSM6427 in 50 L PBS was intravitreally injected with a 30-gauge needle via the same hole as the pipette; three control rabbits were injected with PBS (vehicle) alone. Both 3-and 7-day time points were examined. In the 3-day group, JSM6427 or vehicle injections were administered on either day 0 (immediately after creating the detachment) or 24 hours later (day 1). On postdetachment day 3, 10 g BrdU (Sigma-Aldrich) in 50 L BSS was injected intravitreally and euthanatization (120 mg/kg intravenous sodium pentobarbital; Henry Schein, Inc.) was performed 4 hours later, after which retinal tissues were harvested. These experiments established that injection on postdetachment day 1 was more effective than on day 0; therefore, in the 7-day experiment, injections were administered on postdetachment day 1, bromodeoxyuridine (BrdU) was again administered on day 3, and euthanatization was performed on day 7.
The rabbit eyes were enucleated and fixed (4% paraformaldehyde/ 0.1 M sodium cacodylate buffer, pH 7.4; Electron Microscopy Sciences, Fort Washington, PA). Retinal tissue (ϳ3 mm 2 ) was excised from three detached regions of the JSM6427-and vehicle-treated eyes and from three regions from the nondetached control eyes. Tissues were rinsed in PBS, embedded in low-melt agarose (5%; Sigma-Aldrich), and sectioned at 100 m (Vibratome; Technical Products International, Warrington, PA). The sections were incubated in normal donkey serum (1:20) in PBS/0.5% BSA/0.1% Triton X-100/0.1% sodium azide (PBTA) and pretreated with 2 N HCl for 1 hour to facilitate detection of the BrdU. After the sections were rinsed in PBTA, pooled primary antibodies or lectin were added in PBTA overnight at 4°C. Anti-BrdU (1:200; Accurate Chemical and Scientific Corp., Westbury, NY) was used to label dividing cells, anti-vimentin (1:500; Dako) was used to label Müller cells, and isolectin B4 Griffonia simplicifolia (1:50; Vector Laboratories, Burlingame, CA) was used to label microglia and macrophages. After the sections were washed in PBTA, they were incubated with pooled secondary antibodies (streptavidin CY5, donkey anti-rat CY3, and donkey anti-mouse CY2, all at 1:200 in PBTA; Jackson ImmunoResearch, West Grove, PA) then washed in PBTA. They were mounted with 5% n-propyl gallate/glycerol, and single-plane images were taken from at least four sections from three different regions within each eye (Fluoview 500 laser scanning confocal microscope; Olympus, Tokyo, Japan) to quantify BrdU-labeled cells or subretinal scars and to measure the length of subretinal scars. Labeled cells (either anti-BrdU/vimentin or isolectin B4) were counted per millimeter of retina from the stored images by using an embedded magnification bar. For each experimental group, at least 24 section areas were quantified. To reveal the morphology of the retina, high-quality images were taken as a Z series of five planes and collapsed as a projection. All values are expressed as the mean Ϯ SEM. Statistical comparisons between treatment groups were analyzed using the paired Student's t-test; P Ͻ 0.05 was considered significant.
RESULTS
In Vitro Characterization of ARPE-19 Cells
After retinal detachment, RPE cells have been found to migrate from the basement membrane 27 and, in contacting the vitreous, exhibit a more motile phenotype that is accompanied by altered integrin expression. 28 In our assays, PMA-activated ARPE-19 cells revealed high surface expression of ␣5 integrin and its corresponding ␤1 subunit as determined by semiquantitative flow cytometry (Fig. 1) . Other FN-binding integrins (␣v␤3, ␣v␤5, and ␣4␤1) were also expressed on ARPE-19 cells but at lower levels than ␣5.
To evaluate the inhibitory potential of the integrin ␣5␤1-specific inhibitor JSM6427 in preventing RPE cell attachment to FN, PMA-activated ARPE-19 cells were allowed to bind to FN in the presence of various concentrations of JSM6427. JSM6427 provided a dose-dependent blockade, with a mean IC 50 of 7.1 Ϯ 2.5 M calculated from four independent experiments; a representative experiment is shown in Figure 2 . Blocking with an ␣5-specific antibody provided a 42% reduction in ARPE-19 adhesion to FN (P Ͻ 0.01) while blocking with antibodies specific for ␣v␤3 and ␣v␤5 did not prevent cell adhesion (Fig. 2) , suggesting that ␣5 is a predominant integrin involved in FN-mediated binding by ARPE-19 cells.
Boyden chamber migration assays (Transwell; VWR International) were used to evaluate the effects of bFGF in inducing 
Integrin Expression in Surgically Excised Human Proliferative Membranes
To determine the level of expression of ␣5␤1 on patient eyes with retinal proliferative diseases, 14 membranes from 13 patients were evaluated by immunohistochemistry (PVR after retinal detachment, n ϭ 8; idiopathic epiretinal membranes, n ϭ 5). Of these 14 membranes, 9 were suitable for semiquantitative analysis of all cell markers; the results of this analysis are presented in Table 1 . Photographs of a membrane from a patient with PVR (case 5) are shown in Figures 4A-F and from a patient with an idiopathic epiretinal membrane (case 2) are shown in Figures 4G-L. All tissues had a consistent and prominent immunoreactivity with all three anti-␣5␤1 antibodies tested (two polyclonal and one monoclonal). Representative images for one of the polyclonal antibodies and the monoclonal antibody are shown in Figures 4A, 4G, 4B , and 4H. The immunoreactivity primarily colocalized with cells that were also positive for CK18 (Figs. 4C, 4I) and CD68 (Figs. 4E, 4K) , respectively, indicating that the cells were most likely of RPE and/or macrophage origin, and occasionally with cells that were positive for factor VIII (Figs. 4F, 4L ). Numerous cells, particularly in the membrane from the patient with the idiopathic epiretinal membrane, were also positive for GFAP (Figs. 4D, 4J) , indicating the glial cell origin of these cells. Generally, there was little reactivity with the factor VIII antibody in these membranes (Figs. 4F, 4L ). In contrast, positive-control retinal tissues from three pyogenic granulomas showed a highly vascularized inflammatory condition characterized by strong ␣5␤1 expression on endothelial and inflammatory cells within the stroma and intense labeling of vascular channels (Fig. 4M) . Negative-control retinal tissues from the glaucomatous eye (Fig. 4N ) and an eye with uveal melanoma showed no appreciable labeling of RPE cells for ␣5␤1 and only minor immunoreactivity in choroidal vessels but not in the choriocapillaris. Retinal vessels also had only minor immunoreactivity with the ␣5␤1 antibodies.
Rabbit Model of Retinal Detachment
To investigate the effects of JSM6427 (1 mg) in preventing the proliferative and scarring changes resulting from retinal detachment, a rabbit model was used. Approximate intraocular levels of JSM6427 were 500 M immediately after injection and 70 M at 24 hours after injection (unpublished data). In this model, BrdU was administered on postdetachment day 3, and the eyes were harvested 4 hours later to examine the effects of JSM6427 on cell proliferation. Another group of similarly treated eyes was harvested on day 7 to examine the effects of JSM6427 on proliferation, inflammation, and subretinal glial scar formation. Representative images from normal, untreated (control) detached, and treated detached rabbit retinal tissues are shown in Figure 5 . No glial scarring was observed on day 3 in either vehicle-or JSM6427-treated eyes.
Intravitreal injection of JSM6427 resulted in a significantly greater inhibition of total cellular proliferation (Müller cells, 
TABLE 1. Semiquantitative Analysis of Immunohistochemical Assay of Membranes from Patients with PVR and Idiopathic Epiretinal Membranes
(a) Polyclonal rabbit anti-␣5␤1 antibody (AB1928), (b) polyclonal rabbit anti-␣5␤1 antibody (AB1921), (c) monoclonal mouse anti-␣5␤1 antibody MAB1968. Staining: ϩϩϩ strong, ϩϩ and ϩ(ϩ) medium, ϩ and (ϩ) weak, Ϫ negative; ND, not determined; iERM, idiopathic epiretinal membrane. microglia, and macrophages) compared with vehicle at postdetachment day 3 when injections were administered at day 0 or day 1 (Fig. 6A) . In addition, JSM6427 provided significantly greater inhibition of the proliferation of Müller cells (Fig. 6B) , microglia (Fig. 6C), and macrophages (Fig. 6D ) compared with vehicle when injections were administered at day 1 postdetachment. In this model, Müller cells comprised the majority of proliferating cells (Fig. 6B) . Both JSM6427 and vehicle injections resulted in significantly greater inhibition of proliferation of total cells and Müller cells when injections were administered on day 1 compared with those administered on day 0 (Figs. 6A, 6B) .
At 7 days postdetachment, retinal sections of eyes injected with JSM6427 on day 1 had significant reductions in the total number of anti-BrdU-positive cells (Fig. 6A) , anti-BrdU-positive Müller cells (Fig. 7A) , isolectin B4-positive cells (macrophages and microglia; Fig. 7B), subretinal scars (Fig. 7C) , and length of subretinal scars (Fig. 7D ) compared with vehicle-injected eyes. JSM6427 significantly inhibited the inflammatory response and glial scarring as demonstrated by the reduction in the number of microglia and macrophages (Fig. 7B) and by the reductions in the number and length of subretinal scars (Figs. 7C, 7D) .
DISCUSSION
The present studies demonstrated that JSM6427 provided dosedependent inhibition of adhesion and migration of RPE cells in response to FN. This provides further support of the important role of ␣5␤1-FN-mediated signaling in the pathogenesis of PVR. Similar results were obtained with JSM6427 in assays using primary human fetal RPE cells (Li R, et al., manuscript in preparation). 29 Our comprehensive evaluation of 14 membranes from 13 patients demonstrated that ␣5␤1 was highly expressed on proliferative membranes but not on normal retinal tissues or RPE cells. This extends the findings of an early study demonstrating that ␣5 and ␤1 were expressed in two eyes with PVR 13 but were not expressed on the normal RPE cell layer. 30 Based on our results, the ␣5␤1-positive cells in proliferative membranes were shown to be not only RPE cells and/or macrophages but also of glial cell origin. These findings are consistent with studies demonstrating glial cells in both PVR membranes 31 and idiopathic epiretinal membranes. 32 In addition, our results of in vitro experiments demonstrating that ␣5␤1 was upregulated on activated ARPE-19 cells are consistent with a study showing that ␣5␤1 is expressed at low levels on quiescent primary human RPE cells and is upregulated on proliferating cells. 33 Since RPE cells appear to mediate the contraction of epiretinal membranes in PVR, 27 the upregulation of ␣5␤1 during transdifferentiation and its interaction with FN may be an important step in the disease pathogenesis by leading to the fibrotic response and contraction of membranes after retinal detachment.
In addition to RPE cells, the pathogenesis of PVR involves a wide variety of other cell types such as monocyte/macrophages, microglia, glial cells such as Müller cells, and fibroblasts/myofibroblasts. In our immunohistochemical analysis, we demonstrated co-localized expression of ␣5␤1 with these cell types, supporting their role in PVR pathogenesis. In the study of retinal detachment in the rabbit, JSM6427 significantly reduced the intraretinal proliferation of Müller cells and the presence of inflammatory cells (microglia and macrophages) while also reducing the number and length of subretinal glial scars. Previous studies in animal models have demonstrated that the gliotic response leading to the formation of subretinal scarring begins within 1 day of a retinal detachment and is associated with increased expression of GFAP and vimentin and that the glial membranes continue to expand for as long as the retina remains detached. 34, 35 Experimental retinal detachment was also shown to promote increased proliferation of all nonneuronal cell types that begins within a day after detachment, peaks between days 3 and 4, and continues at low levels for
FIGURE 4. Expression of ␣5␤1 integrin in a representative membrane from a patient with PVR (case 5, A-F) and idiopathic epiretinal membrane (case 2, G-L). Integrin ␣5␤1 was detected using either a polyclonal ␣5␤1 antibody (A, G) or a monoclonal ␣5␤1 antibody (B, H). A CK18-specific antibody was used to label retinal pigment epithelium (RPE) cells (C, I), a GFAP-specific antibody was used to label glial cells (D, J), a CD68-specific antibody was used to label macrophages (E, K), and a factor VIII-specific antibody was used to label endothelial cells (F, L). The positive-control pyogenic granuloma (M) shows intense labeling with the ␣5␤1-specific antibody on endothelial (arrow, vessels) and inflammatory (arrowhead) cells within the stroma. The negative-control glaucomatous eye (N) showed no labeling of RPE cells (arrow) and only minor immunoreactivity in choroidal vessels (arrowheads) but not in the choriocapillaris. Magnification: (A-E, G-L) ϫ20; (M) ϫ10; (N) ϫ40.
weeks after detachment. 36 -38 It is not known what role, if any, this proliferation plays in the formation of glial scars. Also, it is not known if JSM6427 affects glial scar formation through its antiproliferative effects or by some other mechanism, perhaps by inhibiting the expansion of Müller cells into the subretinal space. The fact that integrins mediate proliferation and migration may indicate, however, that JSM6427 affects both events.
It is interesting that the inhibitory effects of JSM6427 on cellular proliferation in our rabbit retinal detachment model were greater when the agent was administered 1 day after detachment than when given immediately after detachment. The reasons for this are unknown. One possibility is that the needle puncture on day 1 caused a "rescue" effect mediated by upregulation and release of endogenous survival factors. 39 This possibility would also explain the slight inhibitory effect of the vehicle injection comparing day 0 and day 1. Another possibility is that JSM6427 is quite rapidly eliminated (GZ, unpublished data, 2008), as generally occurs for small molecules after intravitreal injection, 40 and that the key steps initiating pathogenesis in this rabbit model take place at least 1 day after detachment.
Although the current rabbit model did not permit a detailed analysis of RPE cells, it is likely that RPE cells had an effect on other cell types. During the pathogenesis of PVR, a shift from cell-cell to cell-substrate contacts promotes the transdifferentiation of RPE cells, 41, 42 resulting in morphologic changes and expression of growth factors and extracellular matrix proteins. 16, 43 RPE cell-derived growth factors can act not only in an autocrine manner but also in a paracrine manner to activate Müller cells 43, 44 ; the reverse situation also occurs, in that Mül-ler cells secrete factors that activate RPE cells.
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Integrin ␣v␤5 is the only integrin expressed on the apical surface of RPE cells in the mammalian eye, where it controls the phagocytosis of photoreceptor outer segments [45] [46] [47] [48] and probably the adhesion of RPE cells to the retina. 47 In contrast, integrins ␣v␤3, ␣6␤1, and ␣3␤1 are expressed on the basal lateral membrane of RPE cells where they enable their attachment to Bruch's membrane. 49 Moreover, in our studies, ␣5␤1 was highly expressed on surgically excised proliferative membranes, and proliferating and migrating RPE cells in vitro, yet normal retinal tissues showed little ␣5␤1 expression. Together, these findings suggest that no impairment of physiological RPE function is to be expected during pharmacological therapy that specifically targets ␣5␤1.
The integrin ␣5␤1-FN interaction is a promising target for the treatment of PVR with the potential to inhibit multiple pathogenic pathways, including the intraretinal proliferation and migration of RPE cells, the proliferation of Müller cells, the inflammatory response and resulting fibrosis, and, most likely, the transdifferentiation of RPE cells, the activation of Müller cells, and the response after the contraction of epiretinal membranes. Among these pathogenic processes, the activated Mül-ler cells 11 and transdifferentiated RPE cells 50 are proposed to be the most important triggers of PVR. JSM6427 resulted in inhibition of multiple ␣5␤1-mediated effects in vitro and in vivo, suggesting that it provides therapeutic benefits in the treatment of PVR.
